Assessment of bone dysplasia by micro-CT and glycosaminoglycan levels in mouse models for mucopolysaccharidosis type I, IIIA, IVA, and VII

Journal of Inherited Metabolic Disease

Volumn 36, Issue 2, 2013, Pages 235-246

  Rowan, Daniel J ^a   Tomatsu, Shunji ^b   Grubb, Jeffrey H ^a   Montaño, Adriana M ^a   Sly, William S ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSAMINOGLYCAN; HEPARAN SULFATE; KERATAN SULFATE; BIOLOGICAL MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE DYSPLASIA; BONE RADIOGRAPHY; DISEASE SEVERITY; ENZYME BLOOD LEVEL; HISTOPATHOLOGY; HURLER SYNDROME; IMAGE ANALYSIS; MICRO-COMPUTED TOMOGRAPHY; MOLECULAR MECHANICS; MORQUIO SYNDROME; MOUSE; MUCOPOLYSACCHARIDOSIS TYPE 7; NONHUMAN; OSTEOSCLEROSIS; SANFILIPPO SYNDROME; VERTEBRAL CANAL; ANIMAL; BLOOD; BONE; C57BL MOUSE; CARTILAGE CELL; DISEASE MODEL; FEMALE; HUMAN; KNOCKOUT MOUSE; MALE; METABOLISM; MUCOPOLYSACCHARIDOSIS; PATHOLOGY; PHYSIOLOGY; PROCEDURES; RADIOGRAPHY;

ANIMALS; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE DISEASES, DEVELOPMENTAL; CHONDROCYTES; DISEASE MODELS, ANIMAL; FEMALE; GLYCOSAMINOGLYCANS; HEPARITIN SULFATE; HUMANS; KERATAN SULFATE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUCOPOLYSACCHARIDOSES; SPINAL CANAL; X-RAY MICROTOMOGRAPHY;

EID: 84878502390     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-012-9522-x     Document Type: Article

References (29)

1. Aldenhoven M, Sakkers RJB, Boelens J, de Koning TJ, Wulffraat NM (2009) Musculoskeletal manifestations of lysosomal storage disorders. Ann Rheum Dis 68:1659-1665
2. Bhattacharyya R, Gliddon B, Beccari T, Hopwood JJ, Stanley P (2001) A novel missense mutation in lysosomal sulfamidase is the basis of MPS III A in a spontaneous mouse mutant. Glycobiology 11:99-103
3. Bhaumik M, Muller VJ, Rozaklis T et al (1999) A mouse model for mucopolysaccharidosis type III A (Sanfilippo syndrome). Glycobiology 9:1389-1396
4. Birkenmier EH, Davisson MT, Beamer WG et al (1989) Murine mucopolysaccharidosis type VII. Characterization of a mouse with beta-glucuronidase deficiency. J Clin Invest 83:1258-1266
5. Clarke LA, Russell CS, Pownall S et al (1997) Murine mucopolysaccharidosis type I: targeted disruption of the murine α-L-iduronidase gene. Hum Mol Genet 6:503-511
6. Ernst M, Oates A, Dunn AR (1996) Gp130-mediated signal transduction in embryonic stem cells involves activation of Jak and Ras/mitogen-activated protein kinase pathways. J Biol Chem 271:30136-30143
7. Fraldi A, Hemsley K, Crawley A et al (2007) Functional correction of CNS lesions in an MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes. Hum Mol Genet 16:2693-2702
8. Gaffen JD, Gleave SJ, Crossman MV, Bayliss MT, Mason RM (1995) Articular cartilage proteoglycans in osteoarthritic STR/Ort mice. Osteoarthritis Cartilage 3:95-104
9. Garcia AR, Pan J, Lamsa JC, Muenzer J (2007) The characterization of a murine model of mucopolysaccharidosis II (Hunter syndrome). J Inherit Metab Dis 30:924-934
10. Grimaud E, Blanchard F, Charrier C, Gouin F, Redini F, Heymann D (2002) Leukaemia inhibitory factor (lif) is expressed in hypertrophic chondrocytes and vascular sprouts during osteogenesis. Cytokine 20:224-230
11. Grubb JH, Vogler C, Tan Y, Shah GN, MacRae AF, Sly WS (2008) Infused Fc-tagged β-glucuronidase crosses the placenta and produces clearance of storage in utero in mucopolysaccharidosis VII mice. Proc Natl Acad Sci U S A 105:8375-8380
12. Haskins ME (2007) Animal models for mucopolysaccharidosis disorders and their clinical relevance. Acta Paediatr 96:56-62
13. Heinrich PC, Behrmann I, Müller-Newen G, Schaper F, Graeve L (1998) Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 334:297-314
14. Herati RS, Ma X, Tittiger M, Ohlemiller KK, Kovacs A, Ponder KP (2008) Improved retroviral vector design results in sustained expression after adult gene therapy in mucopolysaccharidosis I mice. J Gene Med 10:972-982
15. Jung SC, Park ES, Choi EN, Kim CH, Kim SJ, Jin DK (2010) Characterization of a novel mucopolysaccharidosis type II model mouse and recombinant AAV2/8 vector-mediated gene therapy. Mol Cells 30:13-18
16. Klüppel M, Wight TN, Chan C, Hinek A, Wrana JL (2005) Maintenance of chondroitin sulfation balance by chondroitin-4-sulfotransferase 1 is required for chondrocyte development and growth factor signaling during cartilage morphogenesis. Development 132:3989-4003
17. Kodama H, Fukuda K, Pan J et al (1997) Leukemia inhibitory factor, a potent cardiac hypertrophic cytokine, activates the JAK/STAT pathway in rat cardiomyocytes. Circ Res 81:656-663
18. Nazarian A, Snyder BD, Zurakowski D, Muller R (2008) Quantitative micro-computed tomotraphy: a non-invasive method to assess equivalent bone mineral density. Bone 43:302-311
19. Neufeld EF, Muenzer J (2001) The mucopolysaccharidosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 3421-3452
20. Oberle S, Schober A, Meyer V et al (2006) Loss of leukemia inhibitory factor receptor beta or cardiotrophin-1 causes similar deficits in preganglionic sympathetic neurons and adrenal medulla. J Neurosci 26:1823-1832
21. Rani MR, Leaman DW, Han Y et al (1999) Catalytically active TYK2 is essential for interferon-beta-mediated phosphorylation of STAT3 and interferonalpha receptor-1 (IFNAR-1) but not for activation of phosphoinositol 3-kinase. J Biol Chem 274:32507-32511
22. Sims NA, Jenkins BJ, Nakamura A et al (2005) Interleukin-11 receptor signaling is required for normal bone remodeling. J Bone Miner Res 20:1093-1102
23. Sly WS, Vogler C, Grubb JH et al (2001) Active site mutant transgene confers tolerance to human β-glucuronidase without affecting the phenotype of MPS VII mice. Proc Natl Acad Sci U S A 98:2205-2210
24. Stewart CL, Kaspar P, Brunet LJ, Bhatt H, Gadi I, Köntgen F, Abbondanzo SJ (1992) Blastocyst implantation depends on maternal expression of leukaemia inhibitory factor. Nature 359:76-79
25. -/-) produced by targeted disruption of the gene defective in Morquio A disease. Hum Mol Genet 12:3349-3358
26. Tomatsu S, Gutierrez M, Nishioka T et al (2005a) Development of MPS IVA mouse. Genet 14:3321-3335
27. Tomatsu S, Okamura K, Maeda H et al (2005b) Keratan sulphate levels in mucopolysaccharidosis and mucolipidoses. J Inherit Metab Dis 28:187-202
28. tm(C76S)slu) of MPS IVA with missense mutation at the active site cystine conserved among sulfatase proteins. Mol Genet Metab 91:251-258
29. Tomatsu S, Montano AM, Dung VC et al (2010) Enhancement of drug delivery: enzyme-replacement therapy for murine Morquio A syndrome. Mol Ther 18:1094-1102